Sign up to save your podcasts
Or
Share Instant Insights: Decoding MASLD (7 min)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Instant Insights: Decoding MASLD (7 min)
This special episode of Healthier World designed to give you Instant Insights discusses the importance of screening and managing fatty liver disease, a condition affecting 1 in 3 Americans and over 70% of patients with type 2 diabetes. The episode covers the transition from the term NAFLD to MASLD, discusses the AACE-recommended testing algorithm for MASLD using the fibrosis-4 (FIB-4) score and the enhanced liver fibrosis (ELF) and highlights the importance of early identification and intervention for proper management of underlying metabolic conditions.
This episode will
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: October 2025
Speaker(s): Maeson Latsko, PhD
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD; Millicent Kee, MSN, FNP-BC
Additional Resources
Quest Diagnostics Clinical Education Center [Link]
ELF test detail
FIB4 test summary
2022 AACE algorithm for fatty liver assessment
Ordering information:
CMP + Fib4
Enhanced Liver Fibrosis Score
References:
Ciardullo S, Vergani M, Perseghin G. Nonalcoholic fatty liver disease in patients with type 2 diabetes: Screening, Diagnosis, and Treatment. J Clin Med. 2023;12(17):5597. doi:10.3390/jcm12175597
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323
Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528-562. doi:10.1016/j.eprac.2022.03.010
Stern C, Castera L. Identification of high-risk subjects in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S196-S206. doi:10.3350/cmh.2022.0431
View all episodes
By Quest DiagnosticsThis special episode of Healthier World designed to give you Instant Insights discusses the importance of screening and managing fatty liver disease, a condition affecting 1 in 3 Americans and over 70% of patients with type 2 diabetes. The episode covers the transition from the term NAFLD to MASLD, discusses the AACE-recommended testing algorithm for MASLD using the fibrosis-4 (FIB-4) score and the enhanced liver fibrosis (ELF) and highlights the importance of early identification and intervention for proper management of underlying metabolic conditions.
This episode will
To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.
Date: October 2025
Speaker(s): Maeson Latsko, PhD
Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD; Millicent Kee, MSN, FNP-BC
Additional Resources
Quest Diagnostics Clinical Education Center [Link]
ELF test detail
FIB4 test summary
2022 AACE algorithm for fatty liver assessment
Ordering information:
CMP + Fib4
Enhanced Liver Fibrosis Score
References:
Ciardullo S, Vergani M, Perseghin G. Nonalcoholic fatty liver disease in patients with type 2 diabetes: Screening, Diagnosis, and Treatment. J Clin Med. 2023;12(17):5597. doi:10.3390/jcm12175597
Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323
Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528-562. doi:10.1016/j.eprac.2022.03.010
Stern C, Castera L. Identification of high-risk subjects in nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S196-S206. doi:10.3350/cmh.2022.0431